UNLABELLED: A previous study found improvements in verbal declarative memory in patients with Posttraumatic Stress Disorder (PTSD) following one year of open-label paroxetine treatment. The purpose of the present study was to replicate prior findings and to extend the previous study by comparing the effects of paroxetine versus placebo on cognition in patients with PTSD. METHODS:Eighteen participants with PTSD underwent assessment of neuropsychological function, following which they were randomized to receive controlled-release (CR) paroxetine or placebo, given in a variable dose in a double- blind manner for three months. Neuropsychological testing was then repeated. Subjects who had received placebo were then treated with open-label paroxetine CR and re-assessed. RESULTS:Paroxetine CR treatment resulted in a significant increase in verbal declarative memory function in the group as a whole, as measured by the Wechsler Memory Scale-Revised, the Selective Reminding Test, and novel paragraph recall, and explicit recall of neutral words. Although we found patterns of improved test performance with paroxetine versus placebo treatment, these differences were not statistically significant. CONCLUSION: These findings replicate an earlier finding that open label treatment with paroxetine CR is associated with improvements in verbal declarative memory function. The current study did not show a statistically significant difference between the effects of paroxetine and placebo on memory function, which may in part be related to our small sample size.
RCT Entities:
UNLABELLED: A previous study found improvements in verbal declarative memory in patients with Posttraumatic Stress Disorder (PTSD) following one year of open-label paroxetine treatment. The purpose of the present study was to replicate prior findings and to extend the previous study by comparing the effects of paroxetine versus placebo on cognition in patients with PTSD. METHODS: Eighteen participants with PTSD underwent assessment of neuropsychological function, following which they were randomized to receive controlled-release (CR) paroxetine or placebo, given in a variable dose in a double- blind manner for three months. Neuropsychological testing was then repeated. Subjects who had received placebo were then treated with open-label paroxetine CR and re-assessed. RESULTS:Paroxetine CR treatment resulted in a significant increase in verbal declarative memory function in the group as a whole, as measured by the Wechsler Memory Scale-Revised, the Selective Reminding Test, and novel paragraph recall, and explicit recall of neutral words. Although we found patterns of improved test performance with paroxetine versus placebo treatment, these differences were not statistically significant. CONCLUSION: These findings replicate an earlier finding that open label treatment with paroxetine CR is associated with improvements in verbal declarative memory function. The current study did not show a statistically significant difference between the effects of paroxetine and placebo on memory function, which may in part be related to our small sample size.
Authors: T V Gurvits; M E Shenton; H Hokama; H Ohta; N B Lasko; M W Gilbertson; S P Orr; R Kikinis; F A Jolesz; R W McCarley; R K Pitman Journal: Biol Psychiatry Date: 1996-12-01 Impact factor: 13.382
Authors: J D Bremner; P Randall; T M Scott; R A Bronen; J P Seibyl; S M Southwick; R C Delaney; G McCarthy; D S Charney; R B Innis Journal: Am J Psychiatry Date: 1995-07 Impact factor: 18.112
Authors: J Cobb Scott; Georg E Matt; Kristen M Wrocklage; Cassandra Crnich; Jessica Jordan; Steven M Southwick; John H Krystal; Brian C Schweinsburg Journal: Psychol Bull Date: 2014-11-03 Impact factor: 17.737
Authors: Borwin Bandelow; David Baldwin; Marianna Abelli; Blanca Bolea-Alamanac; Michel Bourin; Samuel R Chamberlain; Eduardo Cinosi; Simon Davies; Katharina Domschke; Naomi Fineberg; Edna Grünblatt; Marek Jarema; Yong-Ku Kim; Eduard Maron; Vasileios Masdrakis; Olya Mikova; David Nutt; Stefano Pallanti; Stefano Pini; Andreas Ströhle; Florence Thibaut; Matilde M Vaghi; Eunsoo Won; Dirk Wedekind; Adam Wichniak; Jade Woolley; Peter Zwanzger; Peter Riederer Journal: World J Biol Psychiatry Date: 2016-07-15 Impact factor: 4.132
Authors: James Douglas Bremner; Nil Z Gurel; Matthew T Wittbrodt; Mobashir H Shandhi; Mark H Rapaport; Jonathon A Nye; Bradley D Pearce; Viola Vaccarino; Amit J Shah; Jeanie Park; Marom Bikson; Omer T Inan Journal: J Pers Med Date: 2020-09-09